Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-d-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent with the potential to target the glucose transporter system. PATIENTS AND METHODS: Twenty-one patients (10 women and 11 men; median age, 56 years) with refractory solid tumors were treated with doses ranging from 800 to 6,000 mg/m 2. Glufosfamide was administered every 3 weeks as a two-step (fast/slow) intravenous infusion over a 6-hour period. All patients underwent pharmacokinetic sampling at the first course. RESULTS: The MTD was 6,000 mg/m 2. At this dose, two of six patients developed a reversible, dose-limiting renal tubular acidosis and a slight increase in serum creatinine the week after the second and third courses of treatment, respectively, whereas three of six patients experienced short-lived grade 4 neutropenia/leukopenia. Other side effects were generally mild. Pharmacokinetics indicated linearity of area under the time–versus-concentration curve against dose over the dose range studied and a short elimination half-life. There was clear evidence of antitumor activity, with a long-lasting complete response of an advanced pancreatic adenocarcinoma and minor tumor shrinkage of two refractory colon carcinomas and one heavily pretreated breast cancer. CONCLUSION: The principal toxicity of 6-hour infusion of glufosfamide is reversible renal tubular acidosis, the MTD is 6,000 mg/m 2, and the recommended phase II dose is 4,500 mg/m 2. Close monitoring of serum potassium and creatinine levels is suggested for patients receiving glufosfamide for early detection of possible renal toxicity. Evidence of antitumor activity in resistant carcinomas warrants further clinical exploration of glufosfamide in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Over-expression of facilitative glucose transporter genes in human cancer
Yamamoto, T., Seino, Y., Fukumoto, H., Koh, G., Yano, H., Inagaki, N., Yamada, Y., Inoue, K., Manabe, T., & Imura, H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91263-r · Cited by 465
Cited by
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Glucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Metadata
- Authors
- Briasoulis, E., Judson, I., Pavlidis, N., Beale, P., Wanders, J., Groot, Y., Veerman, G., Schuessler, M., Niebch, G., Siamopoulos, K., Tzamakou, E., Rammou, D., Wolf, L., Walker, R., & Hanauske, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-10-20
- Volume
- 18
- Issue
- 20
- Pages
- 3535-3544
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2275696478
- Cited by
- 60
- References
- 1
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.